Tags

Type your tag names separated by a space and hit enter

[Pregabalin (Lyrica) and neuropathic pain syndromes].
Rev Med Brux. 2006 Sep-Oct; 27(5):445-50.RM

Abstract

Pregabalin is a novel central nervous system (CNS) drug with no interaction at benzodiazepine or GABA receptor. Its mechanism of action is correlated with its high affinity for the alpha/delta submit of the voltage-dependant CNS calcium channel. Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys. Pharmacokinetics are linear and predictable across the therapeutic dose range (150-600 mg/ day). Pregabalin is indicated, like gabapentin, in the treatment of neuropathic pain syndromes like post-herpetic neuralgia (PHN) and diabetic polyneuropathy (DPN). Efficacy in other neuropathic pain syndromes need further investigations. This paper emphasizes advantages and disadvantages on a clinical point of view.

Authors+Show Affiliations

Service de Neurologie, C.H.U. de Charleroi.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

17144644

Citation

Jacquy, J, et al. "[Pregabalin (Lyrica) and Neuropathic Pain Syndromes]." Revue Medicale De Bruxelles, vol. 27, no. 5, 2006, pp. 445-50.
Jacquy J, Lossignol D, Sternon J. [Pregabalin (Lyrica) and neuropathic pain syndromes]. Rev Med Brux. 2006;27(5):445-50.
Jacquy, J., Lossignol, D., & Sternon, J. (2006). [Pregabalin (Lyrica) and neuropathic pain syndromes]. Revue Medicale De Bruxelles, 27(5), 445-50.
Jacquy J, Lossignol D, Sternon J. [Pregabalin (Lyrica) and Neuropathic Pain Syndromes]. Rev Med Brux. 2006 Sep-Oct;27(5):445-50. PubMed PMID: 17144644.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pregabalin (Lyrica) and neuropathic pain syndromes]. AU - Jacquy,J, AU - Lossignol,D, AU - Sternon,J, PY - 2006/12/6/pubmed PY - 2007/1/12/medline PY - 2006/12/6/entrez SP - 445 EP - 50 JF - Revue medicale de Bruxelles JO - Rev Med Brux VL - 27 IS - 5 N2 - Pregabalin is a novel central nervous system (CNS) drug with no interaction at benzodiazepine or GABA receptor. Its mechanism of action is correlated with its high affinity for the alpha/delta submit of the voltage-dependant CNS calcium channel. Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys. Pharmacokinetics are linear and predictable across the therapeutic dose range (150-600 mg/ day). Pregabalin is indicated, like gabapentin, in the treatment of neuropathic pain syndromes like post-herpetic neuralgia (PHN) and diabetic polyneuropathy (DPN). Efficacy in other neuropathic pain syndromes need further investigations. This paper emphasizes advantages and disadvantages on a clinical point of view. SN - 0035-3639 UR - https://www.unboundmedicine.com/medline/citation/17144644/[Pregabalin__Lyrica__and_neuropathic_pain_syndromes]_ DB - PRIME DP - Unbound Medicine ER -